News
Pharmaceutical Technology on MSN15h
AstraZeneca enters $200m AI cancer pact with Tempus and PathosAstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.
MedPage Today on MSN3d
Is Lung Cancer Screening as Effective Without Risk-Based Selection?Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...
AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...
Nabil Chebab, US Medical Franchise Head, Lung Cancer, AstraZeneca, said: "AstraZeneca is proud to receive the Corporate Honoree recognition from LCRF. We're honored to stand alongside tireless ...
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...
A cancer drug from partners AstraZeneca and Daiichi Sankyo currently ... carries a black box warning for the risk of interstitial lung disease. The companies said more data will be presented ...
Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...
The partnership, now in its second year, features a limited-edition T-shirt and the Body Check Cup in order to encourage more cancer screenings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback